Cargando…
Hematologic malignancies magnify the effect of body mass index on insulin resistance in cancer survivors
Cancer survivors are at increased risk of type 2 diabetes, which usually develops from obesity and insulin resistance. Whether diabetes susceptibility is due to shared risk factors for cancer and insulin resistance or directly related to cancer and its treatment is unknown. We investigated effect mo...
Autores principales: | Sahinoz, Melis, Luther, James M., Mashayekhi, Mona, Jung, Dae Kwang, Ikizler, T. Alp, Engelhardt, Brian G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006273/ https://www.ncbi.nlm.nih.gov/pubmed/35130338 http://dx.doi.org/10.1182/bloodadvances.2021006241 |
Ejemplares similares
-
4164 Body mass index, not chemotherapy is the major predictor of insulin resistance in patients with hematological malignancies
por: Sahinoz, Melis, et al.
Publicado: (2020) -
Effect Modification of Body Mass Index and Kidney Function on Insulin Sensitivity Among Patients With Moderate CKD and Healthy Controls
por: Akwo, Elvis A., et al.
Publicado: (2021) -
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
por: Pagano, Livio, et al.
Publicado: (2022) -
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022) -
Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial
por: Gernsheimer, Terry B., et al.
Publicado: (2022)